AO Spine Reference Centre & Institute of Health & Biomedical Innovation, Queensland University of Technology, Brisbane, Australia

Traumatic spinal cord injury (SCI) is a devastating condition with no curative therapy. Pro-inflammatory therapy has been suggested recently to try and reduce the inhibitory glial scar and promote neural regeneration and healing. The aim of this study is to investigate the potential of sustained delivery of angiogenic/pro-inflammatory growth factors to reduce the secondary degeneration after spinal cord injury.

Adult male Wistar Kyoto rats (200-300g; 12-16weeks old) were subjected to cord hemisections via a T10 laminectomy. Animals were randomised to treatment or control groups after the spinal cord injury had been induced. Treatment consisted of implantation of a mini-osmotic pump capable of delivering 5 micrograms vascular endothelial growth factor (VEGF) and 5 micrograms platelet-derived growth factor (PDGF), via a catheter, to the site of the lesion, over 7 days(n=6). Control animals were subjected to either cord lesion only (n=6) or lesion plus mini-pump delivering PBS (phosphate-buffered saline) solution (n=6). Rats were sacrificed at one month and the spinal cords were harvested and examined by immunohistology, using anti-neurofilament-200 and anti-Glial Acidic Fibrillary Acidic Protein (GFAP) antibodies.

RESULTS: Active treatment spinal cords showed a higher level with aboration of the axonal filament through the defect and more dense neurofilament-200 staining at the lesion site compared to both control groups. The treatment also showed the elevated presence of activated microglia in the lesion, whilst distal to the lesion the microglia and astrocytes retained an unreactive phenotype.

Pro-inflammatory therapy in the rat spinal cord-injury model showed favourable histological findings after sustained delivery of PDGF and VEGF

Introduction: It is well known that the fate of biomaterials is determined by the distribution of proteins attached to the surface from the initial contact with blood or serum. This profile determines wether a material is inert, creates a foreign body response or is bioactive. Bioinert materials, such as polyethylene completely denature surface proteins, whilst materials inducing inflammatory responses are predisposed to complement protein attachment. Bioactive materials such autologous tissue grafts adsorb, but do not denature serum proteins such as fibronectin and Von Willebrand’s factor. This does not interfere with the healing cascade. This aim of this study is to prepare a synthetic bone graft substitute that activates the body’s autologous healing cascade by activating platelets, without activating a complement response through the controlled adsorption of serum proteins.

Methods: Polymers composed of varied concentration of acrylic acid (AA) and comonomers (methyl, ethyl and butyl methacrylates (MMA, EMA, BMA)) were prepared in glass vials by free radical polymerisation. Fresh blood was collected from a healthy donor and pipetted immediately into each chamber. Glass was used as a control. The chambers were incubated at 37o C for 2 hours. The surface morphology was examined using Scanning Electron Microscopy (SEM). Concentration of complement protein C5a and prothrombin fragments 1 and 2 were determined using commercial ELISA kits. Foreign body reaction (FBR) initiated by the biomaterial was estimated by counting leukocytes on clot sections using immunofluorescence.

Results: Extent of coagulation was correlated with plasma concentrations of Prothrombin fragments 1 and 2. These measurements show blood incubated with various polymers composed of different comonomers all promoted the formation of blood clots. It was found that the leukocyte population towards the interface of clot and polymer (AA:MMA) decreased with increasing surface acid concentration (65%AA:MMA 30 leukocytes/0.25mm2, glass 70 leukocytes/0.25mm2 (p< 0.05)). FBR is induced by the activation of complement system. The percentage of C5a concentration detected in blood incubated with various polymers composed of different comonomers relative to normal serum level of C5a (35ng/mL). No significant elevations of C5a were measured from polymer 65% AA:MMA and 65% AA:EMA. Glass induced vigorous complement response as expected. The synergistic combination of surface acid concentration and comonomers had a significant effect on extent of FBR. Increased acid concentration resulted in decreased C5a level with MMA and ET but increased level with BMA.

Discussion: The functional groups exposed on the surface of a material influence whether leukocyte or platelet activation is responsible for the subsequent physiological response. By modifying the combinations of surface acid concentrations and comonomers, we show that a biomaterial with an appropriate surface chemistry promotes the platelet plug formation and coagulation but down regulated foreign body reaction. This study shows that that a biomaterial with the appropriate surface chemistry to evoke the same coagulation response as damaged tissue, mediated through platelet activation and intrinsic and extrinsic coagulation, initiates the initial pathways of the bone healing cascade. This material is a realistic candidate for biomaterial induced bone regeneration.

Introduction: The biological activity of autologous grafts is due to a number of proteins (growth factors) that control bone cell differentiation, proliferation and expression. Several of these have been isolated including; bone morphogenetic proteins 2 and 7. These are commercially available and regularly used with the intention of accelerating fracture healing, repairing critical sized defects and combating bone mineral loss. Whilst it is commonly recognised that multiple growth factors are present at differing times in the healing cascade, the usual delivery, both in the clinic and the laboratory, is of one growth factor delivered over a very short and early time period. Commonly growth factors are delivered in solution or from a collagen sponge and are quickly metabolised in the proteolytic wound healing environment. The physiological need for BMPs is later than the acute delivery at the time of surgery. The aim of this study is to develop a granular protein delivery system that enables controlled release of multiple proteins at a variety of time points.

Methods: A series of homogenous polymer granules 8mm3 were prepared by photo-polymerising 12uL of mixtures of methacrylated adipic acid anhydride (MAAA) and methyl methacrylate (MMA) or MAAA and butyl methacrylate (BMA) with molar ratios ranging from 100- 55 % (MSAA). Into each granule 5ug of a model drug, carmoisine was loaded and 1%w/w of 2,2-dimethoxy-2-phenyl-acetophenone (DMPA) photoinitiator was added per granule. The granules were exposed to UV light at 390nm for 14 minutes. Multilayered granules were prepared photo-polymerising 4uL layers of different monomer compositions in a similar method to the single layered method above. The composition of the multilayered granules was chosen to optimise the release profile. Carmoisine release profiles were determined by UV-visible spectroscopy.

Results: Homogenous granules composed of 100% MAAA released 90% of their payload by 24hrs, those composed of 90:10 MAAA:MMA released by 48hrs those composed of 70:30 MAAA:MMA released by 80hrs those composed of 60:40 MAAA:MMA released by 170hrs those composed of 70:30 MAAA: BMA released by 288hrs and those composed of 60:40 MAAA:BMA released by 456hrs. The multilayered granule had a sustained release of the model drug over the test period of 19 days.

Discussion: The limitation of most drug delivery systems, such as microspheres or collagen, is poor control over the release profile. The drug is ether released instantly or well after it is required. This multilayered composite drug delivery system enables the controlled release of different bioactive compounds at different time points between 0 and 19 days. By altering the drug loading in each layer we were able to sustain the release of one compound over this time period. This technology enables us to switch compounds at a given time points for example delivery of angiogenic factors for one week, proliferative factors for the second week and differentiation factors for the third week. This technology enables the pre-programmed release of multiple growth factors at times in the healing cascade when they meet the physiological need. A controlled release of growth factors at the appropriate time should improve bone healing rates.

Introduction: Acute neurological damage from spinal cord injuries is believed to be localised, however it initiates a cascade of secondary events which usually leads to extensive and permanent neurological deficit. The secondary damage begins with the disruption of the blood-spinal cord barrier which unleashes a protracted inflammatory response. This prolonged inflammatory response is the catalyst for the secondary neurodegeneration and limited repair response that occurs in the chronic phase of a spinal cord injury. In this study it was proposed that the acute delivery of the angiogenic growth factors vascular endothelial growth factor (VEGF) and platelet derived growth factor (PDGF) would mediate inflammation and restore the blood spinal cord barrier. This would minimise the formation of glial scar and reduce the extent of secondary degeneration caudal and cranial to the lesion site.

Methods: Adult male Wistar rats (400g) were anesthetised. Complete laminectomies were performed at T10 and the animals were subjected to T10 hemisection. Animals were randomised to a treatment group (Lesion Control (LC), Gel Control (GC) and Angiogenic Gel (AG)) after the spinal cord was cut. Each treatment group had 6 animals sacrificed 3 months post injury. Sections were stained with antibodies to neurofilament 200, glial fibrillary acidic protein, smooth muscle actin (SMA), and fluorescent secondary antibodies and mounted with DAPI. The lesion size was measured from horizontal histological sections of the midline from 5 animals in each group using Axiovision version 4.6.1.0 (Carl Zeiss Imaging Solutions, Germany).

Results: The mean lesion size for the lesion control group was 2.09mm2, 1.97mm2 for the gel control group and 0.45mm2 for the active gel group. A t-test was used to confirm that the differences between the active gel and the two control groups were statistically significant (AG vs LC p= 0.021 AG vs GC p= 0.026). Histology showed a marked improvement of the morphology of the astrocytes in the treatment group over the control groups indicating that the treatment affected the population of reactive astrocytes. SMA staining showed an increased level of revascularisation in the treated lesions.

Discussion: Spinal cords do not heal because of prolonged inflammation which leads to secondary necrotic events, scar formation and the inhibition of regeneration. In this study we present a method for regulating the post lesion inflammatory signals, significantly reducing post-lesion scar formation. We propose the delivery of VEGF/PDGF significantly increases the permeability of the blood spinal cord barrier to neutrophils and macrophages and promotes angiogenesis observed in the lesion site. This may have two major effects on the progression of the spinal cord injury. Firstly, by increasing the initial influx of inflammatory cells it enables the faster removal of damaged tissue and phagocytosis of apoptotic cells thereby restoring the balance in favour of regulated inflammation and results in a finite and reduced inflammation time. Secondly, combination of VEGF and PDGF provides a robust angiogenic response and reduces ischemia, the population of reactive astrocytes and the capacity to form glial scars. These growth factors appear to moderate the secondary degenerative changes that result from the prolonged inflammation and thus promote the inherent capacity for regeneration.

Introduction Anterior column reconstruction and fusion remains the gold standard of treatment for a number of spinal pathologies. One of the challenges of interbody fusions cages is the footprint of the cage reducing the surface area of endplate available for fusion. Biodegradable polymer implants will over time present a greater area for fusion and may help to reduce problems such as stress shielding, particulate debris and retained foreign body response. Resorbable cages have been have been prepared from a number of different materials, including inorganic composites (eg hydroxyapatite / tricalcium phosphate) and polymers (Poly L-lactide-co-D,L-lactide (PDLLA)). However all of the current options for interbody fusion have reported deficiencies or complications. The synthesis, mechanical properties, and degradation behaviour of two novel biopolymers are presented and the applicability for use as materials in interbody fusion devices is discussed.

Methods Methacrylated adipic anhydride (MAA) and methacrylated sebacic anhydride (MSA) pre-polymers were synthesized by melt condensation. Conversion of the acid to the anhydride was confirmed using 1H nuclear magnetic resonance (NMR) (Bruker, Alexandria, NSW) and FT- Infrared spectroscopy (Nicolet, Waltham MA). These pre-polymers were subsequently co-polymerized with methyl methacrylate (MMA) and 0.25 wt% benzoyl peroxide at 65oC for 16hrs and post-cured at 120oC under vacuum for 2 hrs to form biodegradable networks. The co-polymerization behaviour was monitored by FT-Raman spectroscopy. The compressive mechanical properties of the polymer were determined using an Instron 5567 (Bayswater Vic.). The polymer networks were degraded in phosphate buffered saline (PBS) with various amounts of MAA and MSA.

Results The formation of the pre-polymer was confirmed with the observation of NMR peaks at 5.8 and 6.2 ppm and FT-IR peaks at 1637cm-1. Copolymerization was followed with consecutive FT-IR acquisitions with 100% conversion achieved between 10 and 30 hrs depending on the ratio of MMA to MSA or MAA. Increasing the fraction of methacrylated anhydride slowed the reaction rate.

The compressive strength of the MAA and MSA based copolymers was measured as a function of anhydride concentration. Compressive strength for MMA increased (90±9 to 140±10 Mpa) in an approximately linear manner for MAA concentrations from 10 to 40 wt.% but decreased markedly for MAA concentration of 45% (62±14 Mpa). The compressive strength of MSA decreased exponentially for concentrations ranging from 10 to 45 wt.% (140±18 to 39±1 Mpa).

Discussion The use of poly-L-lactic acid in lumbar interbody cages has been shown to be mechanically feasible with the mechanical strength of the cage material reported to be 93 Mpa (1). The material described here has controlled mechanical properties in the required range as well as a degradation behaviour that lends itself better to spinal applications than current materials